0

Close
 
Upcoming Allied Market Research
2023
Tissue Diagnostics Market

Tissue Diagnostics Market

by Product (Consumables, Instruments), by Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer, Other Diseases), by Technology (Immunohistochemistry (IHC), In-Situ Hybridization (ISH), Digital Pathology and Workflow Management, Special Staining) and by End User (Hospitals, Research Laboratories, Pharmaceutical Companies, Contract Research Organizations): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Medical Devices & Supplies
Report Code: A02376
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Tissue Diagnostics Market

Request Now !

Tissue diagnostics involves removal of tissue (at a micro level) from the patient’s body, which is then processed, analyzed, and tested under the microscope to detect diseases such as cancer. Advancements in the techniques and equipment of tissue diagnostics helps for fast and accurate determination and evaluation of diseases related to the tissues.

Rise in incidences of cancer, rapid increase in aging population, and growth in healthcare expenditure drive the market. However, budget constraints and high degree of consolidation restrain the market growth. In addition, emerging markets and increased use of personalized medicine offer lucrative opportunities for the market growth.

The report segments the tissue diagnostic market on the basis of product, disease, technology, end user, and region. Based on the product, the market is bifurcated into consumables and instruments. Based on diseases, it is classified into breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, and others. Based on technology, it is categorized into immunohistochemistry (IHC), situ hybridization (ISH), digital pathology & workflow management, and special staining. Based on end users, the market is divided into hospitals, research laboratories, pharmaceutical companies, contract research organizations, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players of tissue diagnostics market are Abbott Laboratories, Inc., Agilent Technologies, Inc., Biogenex Laboratories, Cell Signaling Technology, Inc., Danaher Corporation, F. Hoffman-La Roche AG, Sakura Finetek Japan Co., Ltd., Sigma-Aldrich Corporation, Thermo Fisher Scientific, and Bio Sb.

Key Benefits

  • The study provides an in-depth analysis of the tissue diagnostics market, with current trends and future estimations to elucidate the imminent investment pockets.
  • Extensive analysis of the market by product type elucidates various forms of tissue diagnostics market.
  • Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.
  • This report entails the detailed quantitative analysis of the current market trends and estimations which helps identify the prevailing market opportunities.

 Tissue Diagnostics Market Report Highlights

Aspects Details
By Product
  • Consumables
    • Antibodies
    • Kits
    • Reagents
    • Probes
  • Instruments
    • Slide staining systems
    • Scanners
    • Tissue processing system
    • Other instruments
By Disease
  • Breast Cancer
  • Gastric Cancer
  • Lymphoma
  • Prostate Cancer
  • Non-Small Cell Lung Cancer
  • Other Diseases
By Technology
  • Immunohistochemistry (IHC)
  • In-Situ Hybridization (ISH)
  • Digital Pathology and Workflow Management
  • Special Staining
By End User
  • Hospitals, Research Laboratories
  • Pharmaceutical Companies
  • Contract Research Organizations
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Thermo Fisher Scientific, Biogenex Laboratories, Bio Sb, Danaher Corporation, F. Hoffman-La Roche AG, Agilent Technologies, Inc., Sakura Finetek Japan Co., Ltd., Cell Signaling Technology, Inc., Sigma-Aldrich Corporation, Abbott Laboratories, Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: TISSUE DIAGNOSTICS MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Consumables

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Antibodies

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Kits

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Reagents

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Probes

        • 4.2.4.1. Market Size and Forecast

    • 4.3. Instruments

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. Slide staining systems

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Scanners

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Tissue processing system

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Other instruments

        • 4.3.4.1. Market Size and Forecast

  • CHAPTER 5: TISSUE DIAGNOSTICS MARKET, BY DISEASE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Disease

    • 5.2. Breast Cancer

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Gastric Cancer

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Lymphoma

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Prostate Cancer

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Non-Small Cell Lung Cancer

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Other Diseases

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

  • CHAPTER 6: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Technology

    • 6.2. Immunohistochemistry (IHC)

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. In-Situ Hybridization (ISH)

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Digital Pathology And Workflow Management

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Special Staining

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: TISSUE DIAGNOSTICS MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Hospitals, Research Laboratories

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Pharmaceutical Companies

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Contract Research Organizations

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

  • CHAPTER 8: TISSUE DIAGNOSTICS MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Product

      • 8.2.3. Market Size and Forecast, By Disease

      • 8.2.4. Market Size and Forecast, By Technology

      • 8.2.5. Market Size and Forecast, By End User

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Tissue Diagnostics Market

        • 8.2.7.1. Market Size and Forecast, By Product
        • 8.2.7.2. Market Size and Forecast, By Disease
        • 8.2.7.3. Market Size and Forecast, By Technology
        • 8.2.7.4. Market Size and Forecast, By End User

      • 8.2.8. Canada Tissue Diagnostics Market

        • 8.2.8.1. Market Size and Forecast, By Product
        • 8.2.8.2. Market Size and Forecast, By Disease
        • 8.2.8.3. Market Size and Forecast, By Technology
        • 8.2.8.4. Market Size and Forecast, By End User

      • 8.2.9. Mexico Tissue Diagnostics Market

        • 8.2.9.1. Market Size and Forecast, By Product
        • 8.2.9.2. Market Size and Forecast, By Disease
        • 8.2.9.3. Market Size and Forecast, By Technology
        • 8.2.9.4. Market Size and Forecast, By End User

    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Product

      • 8.3.3. Market Size and Forecast, By Disease

      • 8.3.4. Market Size and Forecast, By Technology

      • 8.3.5. Market Size and Forecast, By End User

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Tissue Diagnostics Market

        • 8.3.7.1. Market Size and Forecast, By Product
        • 8.3.7.2. Market Size and Forecast, By Disease
        • 8.3.7.3. Market Size and Forecast, By Technology
        • 8.3.7.4. Market Size and Forecast, By End User

      • 8.3.8. Germany Tissue Diagnostics Market

        • 8.3.8.1. Market Size and Forecast, By Product
        • 8.3.8.2. Market Size and Forecast, By Disease
        • 8.3.8.3. Market Size and Forecast, By Technology
        • 8.3.8.4. Market Size and Forecast, By End User

      • 8.3.9. Italy Tissue Diagnostics Market

        • 8.3.9.1. Market Size and Forecast, By Product
        • 8.3.9.2. Market Size and Forecast, By Disease
        • 8.3.9.3. Market Size and Forecast, By Technology
        • 8.3.9.4. Market Size and Forecast, By End User

      • 8.3.10. Spain Tissue Diagnostics Market

        • 8.3.10.1. Market Size and Forecast, By Product
        • 8.3.10.2. Market Size and Forecast, By Disease
        • 8.3.10.3. Market Size and Forecast, By Technology
        • 8.3.10.4. Market Size and Forecast, By End User

      • 8.3.11. UK Tissue Diagnostics Market

        • 8.3.11.1. Market Size and Forecast, By Product
        • 8.3.11.2. Market Size and Forecast, By Disease
        • 8.3.11.3. Market Size and Forecast, By Technology
        • 8.3.11.4. Market Size and Forecast, By End User

      • 8.3.12. Russia Tissue Diagnostics Market

        • 8.3.12.1. Market Size and Forecast, By Product
        • 8.3.12.2. Market Size and Forecast, By Disease
        • 8.3.12.3. Market Size and Forecast, By Technology
        • 8.3.12.4. Market Size and Forecast, By End User

      • 8.3.13. Rest Of Europe Tissue Diagnostics Market

        • 8.3.13.1. Market Size and Forecast, By Product
        • 8.3.13.2. Market Size and Forecast, By Disease
        • 8.3.13.3. Market Size and Forecast, By Technology
        • 8.3.13.4. Market Size and Forecast, By End User

    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Product

      • 8.4.3. Market Size and Forecast, By Disease

      • 8.4.4. Market Size and Forecast, By Technology

      • 8.4.5. Market Size and Forecast, By End User

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Tissue Diagnostics Market

        • 8.4.7.1. Market Size and Forecast, By Product
        • 8.4.7.2. Market Size and Forecast, By Disease
        • 8.4.7.3. Market Size and Forecast, By Technology
        • 8.4.7.4. Market Size and Forecast, By End User

      • 8.4.8. Japan Tissue Diagnostics Market

        • 8.4.8.1. Market Size and Forecast, By Product
        • 8.4.8.2. Market Size and Forecast, By Disease
        • 8.4.8.3. Market Size and Forecast, By Technology
        • 8.4.8.4. Market Size and Forecast, By End User

      • 8.4.9. India Tissue Diagnostics Market

        • 8.4.9.1. Market Size and Forecast, By Product
        • 8.4.9.2. Market Size and Forecast, By Disease
        • 8.4.9.3. Market Size and Forecast, By Technology
        • 8.4.9.4. Market Size and Forecast, By End User

      • 8.4.10. South Korea Tissue Diagnostics Market

        • 8.4.10.1. Market Size and Forecast, By Product
        • 8.4.10.2. Market Size and Forecast, By Disease
        • 8.4.10.3. Market Size and Forecast, By Technology
        • 8.4.10.4. Market Size and Forecast, By End User

      • 8.4.11. Australia Tissue Diagnostics Market

        • 8.4.11.1. Market Size and Forecast, By Product
        • 8.4.11.2. Market Size and Forecast, By Disease
        • 8.4.11.3. Market Size and Forecast, By Technology
        • 8.4.11.4. Market Size and Forecast, By End User

      • 8.4.12. Thailand Tissue Diagnostics Market

        • 8.4.12.1. Market Size and Forecast, By Product
        • 8.4.12.2. Market Size and Forecast, By Disease
        • 8.4.12.3. Market Size and Forecast, By Technology
        • 8.4.12.4. Market Size and Forecast, By End User

      • 8.4.13. Malaysia Tissue Diagnostics Market

        • 8.4.13.1. Market Size and Forecast, By Product
        • 8.4.13.2. Market Size and Forecast, By Disease
        • 8.4.13.3. Market Size and Forecast, By Technology
        • 8.4.13.4. Market Size and Forecast, By End User

      • 8.4.14. Indonesia Tissue Diagnostics Market

        • 8.4.14.1. Market Size and Forecast, By Product
        • 8.4.14.2. Market Size and Forecast, By Disease
        • 8.4.14.3. Market Size and Forecast, By Technology
        • 8.4.14.4. Market Size and Forecast, By End User

      • 8.4.15. Rest of Asia Pacific Tissue Diagnostics Market

        • 8.4.15.1. Market Size and Forecast, By Product
        • 8.4.15.2. Market Size and Forecast, By Disease
        • 8.4.15.3. Market Size and Forecast, By Technology
        • 8.4.15.4. Market Size and Forecast, By End User

    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Product

      • 8.5.3. Market Size and Forecast, By Disease

      • 8.5.4. Market Size and Forecast, By Technology

      • 8.5.5. Market Size and Forecast, By End User

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Tissue Diagnostics Market

        • 8.5.7.1. Market Size and Forecast, By Product
        • 8.5.7.2. Market Size and Forecast, By Disease
        • 8.5.7.3. Market Size and Forecast, By Technology
        • 8.5.7.4. Market Size and Forecast, By End User

      • 8.5.8. South Africa Tissue Diagnostics Market

        • 8.5.8.1. Market Size and Forecast, By Product
        • 8.5.8.2. Market Size and Forecast, By Disease
        • 8.5.8.3. Market Size and Forecast, By Technology
        • 8.5.8.4. Market Size and Forecast, By End User

      • 8.5.9. Saudi Arabia Tissue Diagnostics Market

        • 8.5.9.1. Market Size and Forecast, By Product
        • 8.5.9.2. Market Size and Forecast, By Disease
        • 8.5.9.3. Market Size and Forecast, By Technology
        • 8.5.9.4. Market Size and Forecast, By End User

      • 8.5.10. UAE Tissue Diagnostics Market

        • 8.5.10.1. Market Size and Forecast, By Product
        • 8.5.10.2. Market Size and Forecast, By Disease
        • 8.5.10.3. Market Size and Forecast, By Technology
        • 8.5.10.4. Market Size and Forecast, By End User

      • 8.5.11. Argentina Tissue Diagnostics Market

        • 8.5.11.1. Market Size and Forecast, By Product
        • 8.5.11.2. Market Size and Forecast, By Disease
        • 8.5.11.3. Market Size and Forecast, By Technology
        • 8.5.11.4. Market Size and Forecast, By End User

      • 8.5.12. Rest of LAMEA Tissue Diagnostics Market

        • 8.5.12.1. Market Size and Forecast, By Product
        • 8.5.12.2. Market Size and Forecast, By Disease
        • 8.5.12.3. Market Size and Forecast, By Technology
        • 8.5.12.4. Market Size and Forecast, By End User

  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Abbott Laboratories, Inc.

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Agilent Technologies, Inc.

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Biogenex Laboratories

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Cell Signaling Technology, Inc.

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Danaher Corporation

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. F. Hoffman-La Roche AG

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Sakura Finetek Japan Co., Ltd.

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Sigma-Aldrich Corporation

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Thermo Fisher Scientific

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Bio Sb

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY (IHC), BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL TISSUE DIAGNOSTICS MARKET FOR IN-SITU HYBRIDIZATION (ISH), BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL TISSUE DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, RESEARCH LABORATORIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. GLOBAL TISSUE DIAGNOSTICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA TISSUE DIAGNOSTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. U.S. TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 27. U.S. TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 28. U.S. TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 29. U.S. TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. CANADA TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 31. CANADA TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 32. CANADA TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 33. CANADA TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. MEXICO TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 37. MEXICO TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE TISSUE DIAGNOSTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 42. EUROPE TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 45. FRANCE TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 46. FRANCE TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 47. GERMANY TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 48. GERMANY TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 49. GERMANY TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 50. GERMANY TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. ITALY TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 52. ITALY TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 53. ITALY TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 54. ITALY TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. SPAIN TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 56. SPAIN TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 57. SPAIN TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 58. SPAIN TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. UK TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 60. UK TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 61. UK TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 62. UK TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 63. RUSSIA TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 64. RUSSIA TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 65. RUSSIA TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 66. RUSSIA TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. REST OF EUROPE TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 68. REST OF EUROPE TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF EUROPE TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 70. REST OF EUROPE TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. ASIA-PACIFIC TISSUE DIAGNOSTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 72. ASIA-PACIFIC TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 73. ASIA-PACIFIC TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 74. ASIA-PACIFIC TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 75. ASIA-PACIFIC TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 76. CHINA TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 77. CHINA TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 78. CHINA TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 79. CHINA TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. JAPAN TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 81. JAPAN TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 82. JAPAN TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 83. JAPAN TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 84. INDIA TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 85. INDIA TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 86. INDIA TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 87. INDIA TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 88. SOUTH KOREA TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH KOREA TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH KOREA TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 92. AUSTRALIA TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 93. AUSTRALIA TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 94. AUSTRALIA TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 95. AUSTRALIA TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 96. THAILAND TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 97. THAILAND TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 98. THAILAND TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 99. THAILAND TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 100. MALAYSIA TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 101. MALAYSIA TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 102. MALAYSIA TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 103. MALAYSIA TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 104. INDONESIA TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 105. INDONESIA TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 106. INDONESIA TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 107. INDONESIA TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 108. REST OF ASIA PACIFIC TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 109. REST OF ASIA PACIFIC TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 110. REST OF ASIA PACIFIC TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 111. REST OF ASIA PACIFIC TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 112. LAMEA TISSUE DIAGNOSTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 113. LAMEA TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 114. LAMEA TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 115. LAMEA TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 116. LAMEA TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 117. BRAZIL TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 118. BRAZIL TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 119. BRAZIL TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 120. BRAZIL TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 121. SOUTH AFRICA TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 122. SOUTH AFRICA TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 123. SOUTH AFRICA TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 124. SOUTH AFRICA TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 125. SAUDI ARABIA TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 126. SAUDI ARABIA TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 127. SAUDI ARABIA TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 128. SAUDI ARABIA TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 129. UAE TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 130. UAE TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 131. UAE TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 132. UAE TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 133. ARGENTINA TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 134. ARGENTINA TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 135. ARGENTINA TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 136. ARGENTINA TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 137. REST OF LAMEA TISSUE DIAGNOSTICS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 138. REST OF LAMEA TISSUE DIAGNOSTICS, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 139. REST OF LAMEA TISSUE DIAGNOSTICS, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 140. REST OF LAMEA TISSUE DIAGNOSTICS, BY END USER, 2022-2032 ($MILLION)
  • TABLE 141. ABBOTT LABORATORIES, INC.: KEY EXECUTIVES
  • TABLE 142. ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 143. ABBOTT LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 144. ABBOTT LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 145. ABBOTT LABORATORIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 147. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 148. AGILENT TECHNOLOGIES, INC.: OPERATING SEGMENTS
  • TABLE 149. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 150. AGILENT TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. BIOGENEX LABORATORIES: KEY EXECUTIVES
  • TABLE 152. BIOGENEX LABORATORIES: COMPANY SNAPSHOT
  • TABLE 153. BIOGENEX LABORATORIES: OPERATING SEGMENTS
  • TABLE 154. BIOGENEX LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 155. BIOGENEX LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 156. CELL SIGNALING TECHNOLOGY, INC.: KEY EXECUTIVES
  • TABLE 157. CELL SIGNALING TECHNOLOGY, INC.: COMPANY SNAPSHOT
  • TABLE 158. CELL SIGNALING TECHNOLOGY, INC.: OPERATING SEGMENTS
  • TABLE 159. CELL SIGNALING TECHNOLOGY, INC.: PRODUCT PORTFOLIO
  • TABLE 160. CELL SIGNALING TECHNOLOGY, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 161. DANAHER CORPORATION: KEY EXECUTIVES
  • TABLE 162. DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 163. DANAHER CORPORATION: OPERATING SEGMENTS
  • TABLE 164. DANAHER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 165. DANAHER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 166. F. HOFFMAN-LA ROCHE AG: KEY EXECUTIVES
  • TABLE 167. F. HOFFMAN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 168. F. HOFFMAN-LA ROCHE AG: OPERATING SEGMENTS
  • TABLE 169. F. HOFFMAN-LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 170. F. HOFFMAN-LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 171. SAKURA FINETEK JAPAN CO., LTD.: KEY EXECUTIVES
  • TABLE 172. SAKURA FINETEK JAPAN CO., LTD.: COMPANY SNAPSHOT
  • TABLE 173. SAKURA FINETEK JAPAN CO., LTD.: OPERATING SEGMENTS
  • TABLE 174. SAKURA FINETEK JAPAN CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 175. SAKURA FINETEK JAPAN CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 176. SIGMA-ALDRICH CORPORATION: KEY EXECUTIVES
  • TABLE 177. SIGMA-ALDRICH CORPORATION: COMPANY SNAPSHOT
  • TABLE 178. SIGMA-ALDRICH CORPORATION: OPERATING SEGMENTS
  • TABLE 179. SIGMA-ALDRICH CORPORATION: PRODUCT PORTFOLIO
  • TABLE 180. SIGMA-ALDRICH CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 181. THERMO FISHER SCIENTIFIC: KEY EXECUTIVES
  • TABLE 182. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 183. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 184. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 185. THERMO FISHER SCIENTIFIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 186. BIO SB: KEY EXECUTIVES
  • TABLE 187. BIO SB: COMPANY SNAPSHOT
  • TABLE 188. BIO SB: OPERATING SEGMENTS
  • TABLE 189. BIO SB: PRODUCT PORTFOLIO
  • TABLE 190. BIO SB: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL TISSUE DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL TISSUE DIAGNOSTICS MARKET
  • FIGURE 3. SEGMENTATION TISSUE DIAGNOSTICS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN TISSUE DIAGNOSTICS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALTISSUE DIAGNOSTICS MARKET
  • FIGURE 11. TISSUE DIAGNOSTICS MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. TISSUE DIAGNOSTICS MARKET SEGMENTATION, BY BY DISEASE
  • FIGURE 15. TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. TISSUE DIAGNOSTICS MARKET SEGMENTATION, BY BY TECHNOLOGY
  • FIGURE 22. TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY (IHC), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. TISSUE DIAGNOSTICS MARKET FOR IN-SITU HYBRIDIZATION (ISH), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. TISSUE DIAGNOSTICS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 27. TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, RESEARCH LABORATORIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 30. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 31. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 32. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 33. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 34. COMPETITIVE DASHBOARD
  • FIGURE 35. COMPETITIVE HEATMAP: TISSUE DIAGNOSTICS MARKET
  • FIGURE 36. Top player positioning, 2022
  • FIGURE 37. ABBOTT LABORATORIES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. ABBOTT LABORATORIES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. ABBOTT LABORATORIES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. AGILENT TECHNOLOGIES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. BIOGENEX LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. BIOGENEX LABORATORIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. BIOGENEX LABORATORIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. CELL SIGNALING TECHNOLOGY, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. CELL SIGNALING TECHNOLOGY, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. CELL SIGNALING TECHNOLOGY, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. DANAHER CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. DANAHER CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. DANAHER CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. F. HOFFMAN-LA ROCHE AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. F. HOFFMAN-LA ROCHE AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. F. HOFFMAN-LA ROCHE AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. SAKURA FINETEK JAPAN CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. SAKURA FINETEK JAPAN CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. SAKURA FINETEK JAPAN CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. SIGMA-ALDRICH CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. SIGMA-ALDRICH CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. SIGMA-ALDRICH CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 61. THERMO FISHER SCIENTIFIC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 63. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 64. BIO SB: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. BIO SB: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 66. BIO SB: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Tissue Diagnostics Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers